Overview
Anxiety disorders caused by drugs typically manifest as heightened anxiety or agitation secondary to pharmacological agents, often requiring intervention to manage behavioral responses effectively. 1Diagnosis
Assess behavioral changes indicative of anxiety post-drug administration.
Evaluate baseline behavior for comparison; use standardized scales like a 100-point visual analog scale for scoring 1.
Consider procedural context and drug history to differentiate from other causes of anxiety.Management
First-line treatments: Dexmedetomidine at 375 μg/m2 or 125 μg/m2, either alone or in combination with butorphanol at 0.4 mg/kg, effectively reduces anxiety and improves behavioral response 1.
Adjunctive measures: Manual restraint can be used but incurs higher personnel costs and opportunity costs compared to pharmacological options 1.Special Populations
No specific data provided for pregnancy, pediatrics, elderly, or comorbidities in the given abstracts 1.Key Recommendations
Utilize dexmedetomidine at 375 μg/m2 or 125 μg/m2, possibly combined with butorphanol 0.4 mg/kg, for managing drug-induced anxiety in dogs to achieve optimal behavioral control (Evidence: Moderate) 1.
Consider the economic implications of manual restraint versus pharmacological sedation, weighing personnel costs and procedural efficiency (Evidence: Expert opinion) 1.
Monitor behavioral responses using standardized scales to evaluate treatment efficacy and adjust interventions accordingly (Evidence: Moderate) 1.References
1 Barletta M, Raffe M. Behavioral response and cost comparison of manual versus pharmacologic restraint protocols in healthy dogs. The Canadian veterinary journal = La revue veterinaire canadienne 2016. link